Clinical Pharmacology at the Indiana University School of Medicine
Internal Medicine
Dr. David A. Flockhart, MD
|
|
Give Review
David Flockhart practices Internal Medicine. He studied medicine at University of Miami Miller School of Medicine. University of Miami Miller School of Medicine is ranked 45/0 in Research/PrimaryCare. Doctor David A. Flockhart, MD is a published physician. He has 101 papers published. The most current publication "Implementation of a pharmacogenomics consult service to support the INGENIOUS trial."
Publications
- Big Data: Challenges and Opportunities for Clinical Pharmacology.
- Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.
- Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
- In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.
- Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
- Steroid Pathway Genes and Neonatal Respiratory Distress After Betamethasone Use in Anticipated Preterm Birth.
- Report of New Haplotype for ABCC2 Gene: rs17222723 and rs8187718 in cis.
- Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.
- Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.
- Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.
- Is personalized medicine achievable in obstetrics?
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
- Prerequisites to Implementing a Pharmacogenomics Program in a Large Healthcare System.
- Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
- Personal DNA donation to energize genomic medicine.
- Citalopram and Escitalopram Plasma Drug and Metabolite Concentrations: Genome-Wide Associations.
- Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
- PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
- Pharmacoepidemiologic and in Vitro Evaluation of Potential Drug-Drug Interactions of Sulfonylureas with Fibrates and Statins.
- One Size Fits One: Pharmacogenetics in Gastroenterology.
- CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer.
- Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
- Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.
- Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-analysis of Heterogeneous Study Populations.
- Regulation of miRNA Expression by Rifampin in Human Hepatocytes.
- PharmGKB summary: tamoxifen pathway, pharmacokinetics.
- Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation.
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention.
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
- C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting.
- Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.
- Is (+)-[(13)C]-pantoprazole better than (±)-[(13)C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?
- An integrated pharmacokinetics ontology and corpus for text mining.
- Amlodipine - Not a Significant Contributor to Clopidogrel Non-Response?
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole.
- Reduced methadone clearance during aromatase inhibition.
- Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
- Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response.
- Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
- Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
- In Silico and In Vitro Identification of MicroRNAs that Regulate HNF4A Expression.
- A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
- Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series.
- Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene.
- Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms.
- Stereoselective pharmacokinetics of stable isotope (+/-)-[(13) C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.
- Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
- Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoids synthesis.
- Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide.
- The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
- Tamoxifen Downregulates Ets-oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction.
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study.
- Pharmacotherapy and Pregnancy: Highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy.
- A Modulated Empirical Bayes Model for Identifying Topological and Temporal Estrogen Receptor alpha Regulatory Networks in Breast Cancer.
- Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
- In vitro cytochrome P450-mediated metabolism of exemestane.
- Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
- Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).
- Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
- Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays.
- Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
- Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.
- Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
- Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy.
- Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.
- Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.
- Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
- Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.
- Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
- Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
- Patient attitudes toward genotyping in an urban women's health clinic.
- Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
- Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
- A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes.
- Germline pharmacogenetics of tamoxifen response: have we learned enough?
- Predicting asparaginase-associated pancreatitis.
- Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
- Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
- The unfinished business of U.S. drug safety regulation.
- Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
- Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
- Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men.
- Effect of cirrhosis and liver transplantation on the gender difference in QT interval.
- The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates.
- Association between the CYP3A5 genotype and blood pressure.
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
- Creating incentives for genomic research to improve targeting of therapies.
- Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
- CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
- Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.
- Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
- Induction of testosterone metabolism by esomeprazole in a CYP2C19*2 heterozygote.
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
- High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia.
- Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial.
- The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a sub...
Schools
University of Miami School of Medicine
Georgetown University Hospital
Doctors Specialties
- Internal Medicine
Accepted Insurances
Education
-
Georgetown University Hospital -
University of Miami Miller School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Sarah J. McKenna, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kaushang A. Gandhi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carrie A. West, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Love, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard L. Stout, MD |
|
|
Dr. Elisabeth D. Kline, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shelagh A. Fraser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew T. Miles, MD |
|
|
Dr. David Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kurt A. Erdelt, MD |
|
|
Dr. Brian T. Robinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George A. Elmes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald C. Brater, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kurt K. Kroenke, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mustafa H. Fidahussein, MD
This Doctor is OpenDoctor Recommended.
|